Putting Evidence Into Practice: Highlights From Toronto

Slides:

Advertisements

Similar presentations

Advancing Care Forward in Squamous Cell Carcinoma of the Head and Neck

Advertisements

Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.

Evolving Standards in HER2-Targeted Adjuvant Therapy for Breast Cancer

Bladder Cancer: A New Era in Treatment

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Caris Molecular Intelligence®

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

Treatment Algorithms in Melanoma: Past, Present, and Future

Improving Survival in Glioblastoma Multiforme

Advanced NSCLC Without Actionable Mutations

Assessing the Impact: New Data in T790+ NSCLC

New Patient Journeys in Non-small cell lung cancer

Progression After Cancer Immunotherapy in Advanced NSCLC

New Standards of Care in ALK-Translocated Advanced NSCLC

Updates in Lung Cancer: Insights From Vienna

Updates and Perspectives on Third-Generation EFGR TKIs in Advanced NSCLC.

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

Letter from Prof Rolf Stahel

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

The Evolving Role of Immunotherapy in NSCLC

Immunotherapy in Pancreatic Cancer: Thinking Outside the Box

Optimizing Management of Advanced Bladder Cancer

Advanced Lung Cancers: What's on the Horizon?

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Case Studies in Unresectable Hepatocellular Carcinoma

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Advancing Care in Genitourinary Cancer: Perspectives From Chicago

Moving Care Forward in Advanced NSCLC

EGFR-Mutated NSCLC and CNS Involvement: the Conundrum

How to Effectively Manage Patients With Cutaneous Squamous Cell Carcinoma.

Personalizing Management in the Care of Patients With Advanced Sarcoma

Evolving Concepts in the Management of Head and Neck Cancers

Chapter 3 Treatment guidelines for NSCLC that does not have targetable driver mutations.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Oncologia Polmonare – AOU S. Luigi Gonzaga, Orbassano (To)

Advances in Immunotherapy for Peanut Allergy

Immune Checkpoint Inhibitors in Lung Cancer

PARP Inhibitors.

Locally Advanced Lung Cancer

Advances in Gastrointestinal Cancers

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Progress of the NSCLC Revolution

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Biomarker Testing: Harnessing All Sides of the Tumor Microenvironment

All for One: Multidisciplinary Management in EGFR-Mutated NSCLC

This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the.

Novel Concepts in the Management of RCC

Debates and Dilemmas, Part 1

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

From Adjuvant to Metastatic in Melanoma

Multidisciplinary Management in Non-Small Cell Lung Cancer (NSCLC)

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

Checkpoint Inhibitors in First-Line Advanced NSCLC

Third-Generation EGFR TKIs

Going Beyond EXTREME in Head and Neck Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Moving Care Forward in Advanced Gastric Cancer

Finding the Right Sequence in Patients With EGFR-Mutated NSCLC

Physiologic vs Chronologic Age

What's on the Horizon in the Management of EGFR-Mutated Lung Cancer?

Immune Checkpoint Inhibitors in Lung Cancer

Physiologic vs Chronologic Age

Presentation transcript:

Putting Evidence Into Practice: Highlights From Toronto

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Entrectinib in Locally Advanced or Metastatic ROS1-Positive NSCLC

TRIDENT-1: Repotrectinib in ROS1-Positive NSCLC

ALTA-1L: Brigatinib vs Crizotinib in ALK TKI-Naive ALK-Positive NSCLC

Long-Term Results From Erlotinib + Atezolizumab in Advanced NSCLC

PD-L1 Expression From FLAURA

Putting Evidence Into Practice: Highlights From Toronto

Poziotinib for EGFR Exon 20 Mutant NSCLC

Poziotinib for HER2 Exon 20 Mutant NSCLC

VISION: Tepotinib for MET Exon 14 Skipping Mutant NSCLC

PROFILE 1001: Crizotinib in MET Exon 14 Skipping Mutant NSCLC

LIBRETTO-001: LOXO-292 in RET-Positive NSCLC

Osimertinib + BLU-667 in EGFR-Mutated NSCLC With Acquired RET Rearrangement

Putting Evidence Into Practice: Highlights From Toronto

LUME-Meso: Nintedanib + Pemetrexed/Cisplatin in Unresectable MPM

Ganetespib + Pemetrexed + Cisplatin or Carboplatin for Pleural Mesothelioma

ALTER 1202: Anlotinib as Third-Line or Beyond for Relapsed SCLC

Lurbinectedin + Doxorubicin in Relapsed SCLC

Putting Evidence Into Practice: Highlights From Toronto

IMpower132: First-Line Atezolizumab + Carboplatin/Cisplatin + Pemetrexed

JAVELIN Lung 200: Avelumab vs Docetaxel in Previously Treated NSCLC

Pembrolizumab for Oligometastatic NSCLC After Locally Ablative Therapy

NELSON: Lung Cancer Screening Trial

NELSON: Mortality Rates by Gender

Putting Evidence Into Practice: Highlights From Toronto

MERIT: Long-Term Nivolumab in MPM

DREAM: Durvalumab + Chemotherapy as First-Line Therapy for MPM

Pembrolizumab in Previously Treated MM

IMpower133: Atezolizumab + Carboplatin + Etoposide in ES-SCLC

Putting Evidence Into Practice: Highlights From Toronto

PACIFIC: OS Data

PACIFIC: OS Subgroups

Hoosier Cancer Research Network LUN 14-179: Consolidation Pembrolizumab

DETERRED: Concurrent Atezolizumab

DETERRED: Safety Data

Cross-Trial Comparison

Abbreviations

Abbreviations (cont)

Abbreviations (cont)